The company's high-throughput sequencing technologies have enabled researchers and clinicians to decode DNA quickly and accurately.
One of the pioneers in commercializing genome sequencing is Illumina. The company's high-throughput sequencing technologies have enabled researchers and clinicians to decode DNA quickly and accurately. In 2007, Illumina launched the MiSeq System, a benchtop sequencer that made genetic analysis more accessible to laboratories worldwide. Today, Illumina's sequencers are instrumental in cancer genomics, rare disease diagnosis, and pharmacogenomics, guiding treatment decisions tailored to an individual's genetic makeup.